

CLAIMS

1. A lipase inhibitor containing, as the active ingredient, at least one substance which is a fat-soluble substance selected from among SLS type triacylglycerols (i.e. symmetric triacylglycerols composed of S which represents a short-chain fatty acid having from 2 to 6 carbon atoms and L which represents a long-chain fatty acid having from 16 to 22 carbon atoms), LUU type and UUL type triacylglycerols (i.e., asymmetric triacylglycerols composed of L which represents a long-chain saturated fatty acid having from 16 to 22 carbon atoms and U which represents an unsaturated fatty acid having from 16 to 22 carbon atoms) and glyceryl ether lipids wherein a long-chain alkyl or alkenyl chain is attached to the 1- or 3-position of the glycerin via an ether bond.

2. The lipase inhibitor according to claim 1, wherein the selected fat-soluble substance as the active ingredient is an SLS type triacylglycerol (i.e., symmetric triacylglycerol composed of S which represents a short-chain fatty acid having from 2 to 6 carbon atoms and L represents a long-chain fatty acid having from 16 to 22 carbon atoms).

3. A lipid absorption inhibitor containing the SLS type triacylglycerol described in claim 2 as the active ingredient.

5 4. An anti-obesity agent containing the SLS type triacylglycerol described in claim 2 as the active ingredient.

10 5. A hyperlipemia ameliorating agent containing the SLS type triacylglycerol described in claim 2 as the active ingredient.

6. A food product containing the agent according to any one of claims 2 to 5.

15

7. A pharmaceutical composition containing the agent according to any one of claims 2 to 5.

20 8. The lipase inhibitor according to claim 1, wherein the selected fat-soluble substance as the active ingredient is LUU type and UUL type triacylglycerols (i.e., asymmetric triacylglycerols composed of L which represents a long-chain saturated fatty acid having from 16 to 22 carbon atoms and U which represents an unsaturated fatty acid
25 having from 16 to 22 carbon atoms).

9. A lipid absorption inhibitor containing the asymmetric triacylglycerol described in claim 8 as the active ingredient.

5

10. An anti-obesity agent containing the asymmetric triacylglycerol described in claim 8 as the active ingredient.

10

11. A hyperlipemia ameliorating agent containing the asymmetric triacylglycerol described in claim 8 as the active ingredient.

15

12. A food product containing the agent according to any one of claims 8 to 11.

13. A pharmaceutical composition containing the agent according to any one of claims 8 to 11.

20

14. The lipase inhibitor according to claim 1, wherein the selected fat-soluble substance as the active ingredient is a glyceryl ether lipid in which a long-chain alkyl or alkenyl chain is attached to the 1- position or the 3- position of the glycerin via an ether bond.

25

15. A lipid absorption inhibitor containing the glyceryl ether lipid described in claim 14 as the active ingredient.

16. An anti-obesity agent containing the glyceryl ether
5 lipid described in claim 14 as the active ingredient.

17. A hyperlipemia ameliorating agent containing the glyceryl ether lipid described in claim 14 as the active ingredient.

10

18. A food product containing the agent according to any one of claims 14 to 17.

19. A pharmaceutical composition containing the agent
15 according to any one of claims 14 to 17.